Nisa Investment Advisors LLC lowered its stake in shares of Humana Inc (NYSE:HUM) by 0.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 68,564 shares of the insurance provider’s stock after selling 293 shares during the quarter. Nisa Investment Advisors LLC owned about 0.05% of Humana worth $17,530,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the stock. Maverick Capital Ltd. boosted its stake in Humana by 150.9% during the second quarter. Maverick Capital Ltd. now owns 1,550,726 shares of the insurance provider’s stock worth $411,408,000 after buying an additional 932,778 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in Humana by 4,141.9% during the 2nd quarter. Nuveen Asset Management LLC now owns 706,911 shares of the insurance provider’s stock worth $187,543,000 after purchasing an additional 690,246 shares during the last quarter. PointState Capital LP bought a new stake in Humana during the 2nd quarter worth about $180,507,000. Marshall Wace North America L.P. raised its holdings in Humana by 6,921.1% during the 2nd quarter. Marshall Wace North America L.P. now owns 536,275 shares of the insurance provider’s stock worth $142,273,000 after purchasing an additional 528,637 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in Humana during the 2nd quarter worth about $115,680,000. 92.93% of the stock is currently owned by institutional investors and hedge funds.
In related news, insider Brian P. Leclaire sold 7,239 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total value of $2,097,138.30. Following the sale, the insider now owns 12,994 shares in the company, valued at approximately $3,764,361.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.54% of the company’s stock.
NYSE:HUM traded up $2.44 during trading hours on Friday, reaching $317.58. 1,173,375 shares of the stock were exchanged, compared to its average volume of 1,220,728. The stock has a market cap of $39.82 billion, a PE ratio of 21.83, a PEG ratio of 1.27 and a beta of 0.85. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.75 and a quick ratio of 1.75. Humana Inc has a twelve month low of $225.65 and a twelve month high of $342.03. The firm has a 50 day moving average of $277.48 and a 200 day moving average of $270.93.
Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, November 6th. The insurance provider reported $5.03 EPS for the quarter, beating the consensus estimate of $4.58 by $0.45. The company had revenue of $16.24 billion during the quarter, compared to the consensus estimate of $16.15 billion. Humana had a return on equity of 22.47% and a net margin of 4.13%. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.58 EPS. Equities research analysts anticipate that Humana Inc will post 17.75 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.69%. The ex-dividend date is Monday, December 30th. Humana’s payout ratio is presently 15.12%.
Several analysts have weighed in on the company. Deutsche Bank assumed coverage on Humana in a report on Thursday, September 12th. They set a “hold” rating and a $300.00 price objective for the company. Piper Jaffray Companies boosted their price objective on Humana from $315.00 to $341.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. SunTrust Banks upped their price target on Humana to $335.00 and gave the company a “hold” rating in a research note on Thursday. They noted that the move was a valuation call. Citigroup upped their price target on Humana from $340.00 to $350.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Morgan Stanley lowered their price target on Humana from $342.00 to $337.00 and set an “overweight” rating for the company in a research note on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $322.63.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Story: What is the price-sales ratio?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.